[Immunoglobulin therapy in patients after autologous and allogeneic bone marrow transplantation].
Following bone marrow transplantation many patients are suffering from an impaired immunoglobulin production. Treatment with intravenous immunoglobulin has significantly reduced the incidence of infections as well as severe graft-versus-host disease during the early posttransplant period. However, no complete protection of the patients has been achieved. According to our own observations, especially patients with a decreased production of IgM antibodies seem to have an increased risk of cytomegalovirus-induced pneumonitis. During the late posttransplant period, patients with IgG subclass deficiency are at risk of acquiring gram-positive infections. However, randomized studies investigating the effect of immunoglobulin treatment during the late posttransplant phase have not yet been conducted.
Körholz
D
D
Klinik für pädiatrische Hämatologie und Onkologie, Heinrich-Heine-Universität, Düsseldorf, BRD.
Grünewald
S
S
Burdach
S
S
Göbel
U
U
D016026:Bone Marrow Transplantation / Q000276:immunology*; D006086:Graft vs Host Disease / Q000276:immunology* / Q000517:prevention & control; D006801:Humans; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000032:analysis / Q000627:therapeutic use; D007075:Immunoglobulin M / Q000032:analysis; D009894:Opportunistic Infections / Q000276:immunology* / Q000517:prevention & control; D018805:Sepsis / Q000276:immunology* / Q000517:prevention & control
D007074:Immunoglobulin G; D007075:Immunoglobulin M
Immunglobulintherapie bei Patienten nach autologer und allogener Knochenmarktransplantation.